Mustang Bio, Inc. Stock price
Is Mustang Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.
Key metrics
Mustang Bio, Inc. Stock Analysis
Analyst Opinions
7 Analysts have issued a Mustang Bio, Inc. forecast:
Analyst Opinions
7 Analysts have issued a Mustang Bio, Inc. forecast:
Mustang Bio, Inc. Events
Upcoming Event
Don't miss a Thing! We will send you all news about Mustang Bio, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mustang Bio, Inc. Stock News
Company Profile
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.
| Head office | United States |
| CEO | Dr. Litchman |
| Employees | 4 |
| Founded | 2015 |
| Website | www.mustangbio.com |


